- Home
- CCEC vs COLL Comparison
CCEC vs COLL Comparison
Compare CCEC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEC
- COLL
- Stock Information
- Founded
- CCEC 2007
- COLL 2002
- Country
- CCEC Greece
- COLL United States
- Employees
- CCEC N/A
- COLL N/A
- Industry
- CCEC Marine Transportation
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- CCEC Consumer Discretionary
- COLL Health Care
- Exchange
- CCEC Nasdaq
- COLL Nasdaq
- Market Cap
- CCEC 1.4B
- COLL 958.8M
- IPO Year
- CCEC 2007
- COLL 2015
- Fundamental
- Price
- CCEC $23.65
- COLL $30.35
- Analyst Decision
- CCEC Buy
- COLL Strong Buy
- Analyst Count
- CCEC 2
- COLL 4
- Target Price
- CCEC $24.00
- COLL $43.75
- AVG Volume (30 Days)
- CCEC 8.1K
- COLL 289.9K
- Earning Date
- CCEC 08-01-2025
- COLL 08-07-2025
- Dividend Yield
- CCEC 2.54%
- COLL N/A
- EPS Growth
- CCEC 44.72
- COLL N/A
- EPS
- CCEC 3.36
- COLL 1.25
- Revenue
- CCEC $402,628,000.00
- COLL $664,283,000.00
- Revenue This Year
- CCEC $19.03
- COLL $20.04
- Revenue Next Year
- CCEC $13.94
- COLL $3.98
- P/E Ratio
- CCEC $40.82
- COLL $24.19
- Revenue Growth
- CCEC 69.94
- COLL 17.17
- 52 Week Low
- CCEC $14.09
- COLL $23.23
- 52 Week High
- CCEC $24.33
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- CCEC N/A
- COLL 54.25
- Support Level
- CCEC N/A
- COLL $29.28
- Resistance Level
- CCEC N/A
- COLL $30.83
- Average True Range (ATR)
- CCEC 0.00
- COLL 0.75
- MACD
- CCEC 0.00
- COLL -0.00
- Stochastic Oscillator
- CCEC 0.00
- COLL 51.63
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.